Renaissance Technologies
COCP icon

Renaissance Technologies’s Cocrystal Pharma COCP Stock Holding History

Renaissance Technologies’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189K Buy
179,628
+55,700
+45% +$68.5K ﹤0.01% 2891
2026
Q1 		$125K Sell
123,928
-2,100
-2% -$2.17K ﹤0.01% 2993
2025
Q4 		$123K Sell
126,028
-1,900
-1% -$2.01K ﹤0.01% 2972
2025
Q3 		$160K Buy
127,928
+2,900
+2% +$4.47K ﹤0.01% 3180
2025
Q2 		$186K Sell
125,028
-600
-0.5% -$893 ﹤0.01% 3186
2025
Q1 		$178K Sell
125,628
-200
-0.2% -$373 ﹤0.01% 3097
2024
Q4 		$254K Sell
125,828
-4,200
-3% -$8.4K ﹤0.01% 3090
2024
Q3 		$229K Buy
130,028
+200
+0.2% +$389 ﹤0.01% 3079
2024
Q2 		$302K Buy
129,828
+3,800
+3% +$7.41K ﹤0.01% 2903
2024
Q1 		$176K Buy
126,028
+900
+0.7% +$1.4K ﹤0.01% 3253
2023
Q4 		$215K Sell
125,128
-1,100
-0.9% -$1.96K ﹤0.01% 3110
2023
Q3 		$236K Buy
126,228
+1,700
+1% +$4.27K ﹤0.01% 3032
2023
Q2 		$298K Buy
124,528
+4,700
+4% +$11.4K ﹤0.01% 3123
2023
Q1 		$238K Buy
119,828
+5,800
+5% +$12.9K ﹤0.01% 3208
2022
Q4 		$222K Sell
114,028
-19,674
-15% -$50.4K ﹤0.01% 3370
2022
Q3 		$467K Sell
133,702
-8,151
-6% -$38.2K ﹤0.01% 2962
2022
Q2 		$698K Sell
141,853
-174
-0.1% -$927 ﹤0.01% 2945
2022
Q1 		$937K Sell
142,027
-16,550
-10% -$110K ﹤0.01% 2771
2021
Q4 		$1.24M Sell
158,577
-10,320
-6% -$106K ﹤0.01% 2495
2021
Q3 		$2.13M Sell
168,897
-47,264
-22% -$625K ﹤0.01% 2040
2021
Q2 		$3.24M Sell
216,161
-138,412
-39% -$2.1M ﹤0.01% 1918
2021
Q1 		$5.91M Buy
354,573
+25,408
+8% +$516K 0.01% 1554
2020
Q4 		$5.37M Buy
329,165
+10,467
+3% +$145K 0.01% 1539
2020
Q3 		$3.56M Buy
318,698
+62,754
+25% +$1.15M ﹤0.01% 1774
2020
Q2 		$4.67M Buy
255,944
+128,992
+102% +$1.58M ﹤0.01% 1684
2020
Q1 		$1.08M Buy
126,952
+116,179
+1,078% +$1.09M ﹤0.01% 2388
2019
Q4 		$64K Buy
10,773
+9,896
+1,128% +$98.8K ﹤0.01% 3369
2019
Q3 		$22K Buy
+877
New +$22.7K ﹤0.01% 3371

Other funds holding COCP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Renaissance Technologies's COCP Position: Q2 2026 in Review

Renaissance Technologies increased its Cocrystal Pharma (COCP) stake by 45% in Q2 2026, buying an estimated $68.5K and bringing the position to 179,628 shares worth $189K. The position accounts for ﹤0.01% of the portfolio, ranked #2891.

Renaissance Technologies first reported a position in COCP in Q3 2019 and has held it in 28 quarters since. The position peaked at $5.91M in Q1 2021. 22 funds tracked by Wall St. Rank hold COCP as of Q2 2026.

  • Renaissance Technologies held 179,628 shares of Cocrystal Pharma worth $189K as of Q2 2026.
  • Renaissance Technologies bought 55,700 Cocrystal Pharma shares in Q2 2026, an estimated $68.5K.
  • Cocrystal Pharma made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2891 holding.
  • Renaissance Technologies first reported a position in Cocrystal Pharma in Q3 2019 and has held it in 28 quarters since.
  • Renaissance Technologies's Cocrystal Pharma position peaked at $5.91M in Q1 2021.
  • 22 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.